<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To determine the effect of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-alpha blocker etanercept on the <z:e sem="disease" ids="C0878631" disease_type="Disease or Syndrome" abbrv="">pathergy</z:e> and monosodium urate (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSU</z:e>) status and on the mucocutaneous and articular manifestations of patients with <z:chebi fb="6" ids="22696">Beh</z:chebi>Ã§et's disease (BD) </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Forty male patients with BD, <z:hpo ids='HP_0000001'>all</z:hpo> with positive <z:e sem="disease" ids="C0878631" disease_type="Disease or Syndrome" abbrv="">pathergy</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSU</z:e> tests and mucocutaneous disease and/or <z:hpo ids='HP_0001369'>arthritis</z:hpo>, were randomized (20 patients to each study arm) to receive either etanercept 25 mg twice a week or placebo for 4 weeks </plain></SENT>
<SENT sid="2" pm="."><plain>The <z:e sem="disease" ids="C0878631" disease_type="Disease or Syndrome" abbrv="">pathergy</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSU</z:e> responses and the frequencies of mucocutaneous and articular manifestations were compared between the 2 groups </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: There were no decreases in the <z:e sem="disease" ids="C0878631" disease_type="Disease or Syndrome" abbrv="">pathergy</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSU</z:e> responses in the etanercept group compared to the placebo group at any time </plain></SENT>
<SENT sid="4" pm="."><plain>The mean numbers of <z:hpo ids='HP_0000155'>oral ulcers</z:hpo>, nodular lesions, and papulopustular lesions were less in the etanercept group compared to the placebo group at <z:hpo ids='HP_0000001'>all</z:hpo> weekly evaluations, except for the second week for papulopustular lesions </plain></SENT>
<SENT sid="5" pm="."><plain>The probability of being free of <z:hpo ids='HP_0000155'>oral ulcers</z:hpo> and nodular lesions was also significantly higher in the former group (log-rank chi-square = 9.83, p = 0.0017; log-rank chi-square = 14.17, p = 0.0002, respectively) </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: Etanercept did not affect the <z:e sem="disease" ids="C0878631" disease_type="Disease or Syndrome" abbrv="">pathergy</z:e> reaction and the cutaneous response to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSU</z:e> crystals </plain></SENT>
<SENT sid="7" pm="."><plain>However, the drug was effective in suppressing most of the mucocutaneous manifestations of BD </plain></SENT>
</text></document>